23 April 2024: Acadia Pharmaceuticals Inc has announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder. Health Canada has granted Priority Review for Acadia’s submission. “Rett syndrome is a profoundly debilitating and complex neurodevelopmental disorder that presents differently across patients and…
Clinical trial for ALS patients
10 April 2024: Axoltis Pharma, a French biopharmaceutical company dedicated to developing therapeutic solutions for neurodegenerative diseases, today announced the authorisation from ANSM, the French agency for the safety of health products, to launch the SEALS study. This phase II clinical trial of drug candidate NX210c in patients with Amyotrophic Lateral Sclerosis (ALS) is the…
Blood tests for diagnosing dementia a step closer for UK
Blood tests for diagnosing dementia are a step closer for UK
Position of stroke patient’s head before surgery may improve neurological function
Research Highlights: from American Stroke Association International Stroke Conference, February 2024 Positioning patients with large vessel ischaemic (clot-caused) stroke with their heads flat (0-degrees) before surgery to remove the blood clot resulted in significant improvements in neurological function, compared to patients whose heads were elevated (at a 30-degree angle), according to science presented on February…
Non-pharmacological migraine treatment
Theranica’s REN Wearable Becomes the First Ever Non-Pharmacological Migraine Treatment to Receive Commercial Coverage in the USA Feb. 20, 2024: Theranica, a prescribed digital therapeutics company specialising in neuromodulation devices for migraine and other idiopathic pain conditions, announced the inclusion of its Nerivio Remote Electrical Neuromodulation (REN) wearable, for use in the acute and preventive…
Is Long COVID a brain injury?
Study led by Benedict Michael finds global cognitive deficits A recent study on Preprint server Research Square suggests that brain fog, memory and concentration problems may be due to brain injury caused by the COVID-19 virus. The study found that 351 patients hospitalised with severe COVID-19 had evidence of a long-term brain injury a year…
Potential treatments for secondary brain cancer
Drugs already licensed could be trialled to potentially treat secondary brain cancer, new research finds The largest review of papers for brain cancer that has spread from the lungs has found abnormalities in the brain cancer. Licensed drugs could be clinically trialled to find out if they could treat the disease. The research led by…
Immune response responsible for neurological damage
There has been a long-held belief that acute viral infections are directly responsible for neurological damage, but researchers from McMaster University have now discovered that it is the immune system’s response that is behind it. The research, published on February 5, 2024 in Nature Communications, was led by Elizabeth Balint, a PhD student at McMaster, and…
Biogen drops Alzheimer’s drug Aduhelm
31 January 2024; Biogen has announced that it will discontinue the development and commercialisation of ADUHELM® (aducanumab-avwa) 100 mg/mL injection for intravenous use and will terminate the ENVISION clinical study. This decision is not related to any safety or efficacy concerns. A large portion of the resources released resulting from termination of the ADUHELM programme will…
